GS
MREO

GTS Securities’s Mereo BioPharma MREO Stock Holding History

GTS Securities’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,664
Closed -$51.7K – 4185
2024
Q1 		$51.7K Buy
+15,664
New +$53K ﹤0.01% 3626

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

GTS Securities's MREO Position: Q2 2024 in Review

GTS Securities sold out of Mereo BioPharma (MREO) in Q2 2024, closing a stake of 15,664 shares — an estimated $51.7K sold.

GTS Securities first reported a position in MREO in Q1 2024 and held it in 1 quarter. The position peaked at $51.7K in Q1 2024. 79 funds tracked by Wall St. Rank hold MREO as of Q2 2024.

  • GTS Securities reported no remaining Mereo BioPharma position as of Q2 2024 after selling out during the quarter.
  • GTS Securities sold 15,664 Mereo BioPharma shares in Q2 2024, an estimated $51.7K.
  • GTS Securities first reported a position in Mereo BioPharma in Q1 2024 and held it in 1 quarter.
  • GTS Securities's Mereo BioPharma position peaked at $51.7K in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2024.

Based on GTS Securities's 13F filing for Q2 2024, filed 14 Aug 2024.